Literature DB >> 18817930

Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process.

Yermi Harel1, Nava Appleboim, Mor Lavie, Anat Achiron.   

Abstract

BACKGROUND AND
PURPOSE: Attention is one of the major cognitive domains adversely affected in multiple sclerosis (MS). The aim of the current study was to determine the effect of a single dose of methylphenidate on cognitive performance of MS patients with significant attention deficit.
METHODS: In a double-blind placebo-controlled study design, 26 MS patients with impaired attention were randomly assigned to receive a single dose of 10 mg methylphenidate or placebo. Attention was assessed using the paced auditory serial addition test for 3 and 2 s (PASAT3'' and PASAT2'') at baseline and 1 h after drug/placebo administration.
RESULTS: Methylphenidate significantly improved performance of both PASAT3'' and PASAT2'' tests by 22.8% and 25.6% respectively (p<0.001), while no significant changes were observed in placebo treated patients.
CONCLUSION: Administration of a single dose of methylphenidate significantly improved attention in MS patients with considerable attention deficit.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817930     DOI: 10.1016/j.jns.2008.08.025

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

1.  The role of neuroplasticity and cognitive reserve in aging with HIV: recommendations for cognitive protection and rehabilitation.

Authors:  David E Vance; Pariya L Fazeli; Joan S Grant; Larry Z Slater; James L Raper
Journal:  J Neurosci Nurs       Date:  2013-10       Impact factor: 1.230

2.  Assessing and treating forgetfulness and cognitive problems in adults with HIV.

Authors:  David E Vance; Pariya L Fazeli; Linda Moneyham; Norman L Keltner; James L Raper
Journal:  J Assoc Nurses AIDS Care       Date:  2013 Jan-Feb       Impact factor: 1.354

3.  Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.

Authors:  Sarah D Broicher; Linard Filli; Olivia Geisseler; Nicole Germann; Björn Zörner; P Brugger; M Linnebank
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

Review 4.  Managing Disability in Progressive Multiple Sclerosis.

Authors:  Divyanshu Dubey; Peter Sguigna; Olaf Stüve
Journal:  Curr Treat Options Neurol       Date:  2016-06       Impact factor: 3.598

Review 5.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

6.  Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.

Authors:  Sarah A Morrow; Heather Rosehart
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

Review 7.  Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.

Authors:  Shumita Roy; Ralph H B Benedict; Allison S Drake; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

8.  Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial.

Authors:  Jesus F Lovera; Edward Kim; Elizabeth Heriza; Mary Fitzpatrick; James Hunziker; Aaron P Turner; Joshua Adams; Thomas Stover; Adam Sangeorzan; Alicia Sloan; Diane Howieson; Katherine Wild; Jodie Haselkorn; Dennis Bourdette
Journal:  Neurology       Date:  2012-09-05       Impact factor: 9.910

Review 9.  Cognitive impairment in multiple sclerosis.

Authors:  Jesus Lovera; Blake Kovner
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 10.  Treatment of cognitive impairment in multiple sclerosis: position paper.

Authors:  Maria Pia Amato; Dawn Langdon; Xavier Montalban; Ralph H B Benedict; John DeLuca; Lauren B Krupp; Alan J Thompson; Giancarlo Comi
Journal:  J Neurol       Date:  2012-11-23       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.